76
|
Ruckhäberle E, Karn T, Hanker L, Schulz-Knappe P, Schwarz J, Engels K, Gaetje R, Holtrich U, Rody A, Kaufmann M. Tandem mass technology: A helpful tool for proteomic research in breast cancer? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
77
|
Woelber L, Eulenburg C, Hager M, Choschzick M, Schwarz J, Dowaji J, Gieseking F, Ihnen M, Jaenicke F, Mahner S. Prognostic relevance of resection margin distance for loco-regional control in vulvar cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
78
|
Fritzsch D, Oberbeck M, Lobsien D, Schwarz J, Hoffmann KT. Suszeptibilitätsgewichtete Bildgebung zerebraler Kerngebiete im 3Tesla-MRT bei Patienten mit idiopathischem Parkinson-Syndrom. ROFO-FORTSCHR RONTG 2010. [DOI: 10.1055/s-0030-1252539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
79
|
Forsterová K, Votavová H, Schwarz J, Karban J, Stuka C, Trněný M. Advanced rai stage in patients with chronic lymphocytic leukaemia correlates with simultaneous hypermethylation of plural tumour suppressor genes. Folia Biol (Praha) 2010; 56:158-164. [PMID: 20974048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Hypermethylation of CpG islands within gene promoters is one of various mechanisms of gene silencing involved in the pathogenesis of human cancer. By using methylation-specific polymerase chain reaction we explored aberrant promoter methylation of five tumour suppressor genes in 29 patients with chronic lymphocytic leukaemia. Aberrant methylation of DLC1, SHP1, p15 and p16 occurred, respectively, in 89.7 %, 70 %, 62.1 % and 31 % of patients at diagnosis. Lamin A/C was unmethylated in all the samples. Hypermethylation of at least one gene was detected in 96.6 % of patients. Concurrent methylation of two or more genes correlated with Rai stage at diagnosis.
Collapse
MESH Headings
- Adult
- Aged
- CpG Islands
- Cyclin-Dependent Kinase Inhibitor p15/genetics
- Cyclin-Dependent Kinase Inhibitor p15/metabolism
- Cyclin-Dependent Kinase Inhibitor p16/genetics
- Cyclin-Dependent Kinase Inhibitor p16/metabolism
- DNA Methylation
- DNA, Neoplasm/genetics
- DNA, Neoplasm/metabolism
- Female
- GTPase-Activating Proteins/genetics
- GTPase-Activating Proteins/metabolism
- Gene Expression Regulation, Neoplastic
- Gene Silencing
- Genes, Tumor Suppressor/physiology
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Polymerase Chain Reaction/methods
- Promoter Regions, Genetic
- Protein Tyrosine Phosphatase, Non-Receptor Type 6/genetics
- Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism
- Tumor Suppressor Proteins/genetics
- Tumor Suppressor Proteins/metabolism
Collapse
|
80
|
Löhle M, Wolz M, Strecker K, Schneider C, Schwanebeck U, Reichmann H, Grählert X, Schwarz J, Storch A. P2.103 Antidyskinetic effects of levetiracetam on levodopa-induced dyskinesias in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70454-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
81
|
Penka M, Schwarz J, Pavlík T, Indrák K, Doubek M, Dulícek P, Pospísilová D, Kissová J, Jonásová A, Jelínková P, Hlusí A, Schutzová M, Cerná O, Brychtová Y, Nováková L, Korístek Z, Segethová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Walterová L, Bodzásová C, Dusek L. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]. VNITRNI LEKARSTVI 2009; 55:I-XII. [PMID: 20017445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis focused mainly on evaluation of anagrelide dosage needed to achieve a complete response in high-risk patients: reduction in platelet count to below 400 x 10(9)/l, which was also considered as reaching the therapeutic goal. The outcomes of the registry confirm that although anagrelide (Thromboreductin) is a very effective platelet-reducing agent, the administration of which is related to a low incidence of adverse effects and complications, the therapeutic goal is not achieved in all cases and or despite a quick treatment response, the therapeutic goal is achieved more slowly.
Collapse
|
82
|
Chen F, Kuhberg M, Skowronek P, Schwarz J, Lichtenegger W, Sehouli J. P51 Nutritional status and clinical outcome of elderly women with primary or recurrent ovarian cancer: results of a prospective study. Crit Rev Oncol Hematol 2009. [DOI: 10.1016/s1040-8428(09)70089-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
83
|
Mahner S, Wölber L, zu Eulenburg C, Schwarz J, Milde-Langosch K, Müller V, Jänicke F. Longitudinale Veränderung und prognostische Bedeutung der Serum-Marker VEGF und TIMP-1 während der Ovarialkarzinom-Primärtherapie. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1238987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
84
|
McKeen S, Grell G, Peckham S, Wilczak J, Djalalova I, Hsie EY, Frost G, Peischl J, Schwarz J, Spackman R, Holloway J, de Gouw J, Warneke C, Gong W, Bouchet V, Gaudreault S, Racine J, McHenry J, McQueen J, Lee P, Tang Y, Carmichael GR, Mathur R. An evaluation of real-time air quality forecasts and their urban emissions over eastern Texas during the summer of 2006 Second Texas Air Quality Study field study. ACTA ACUST UNITED AC 2009. [DOI: 10.1029/2008jd011697] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
85
|
Skowronek P, Kuhberg M, Chen F, Schwarz J, Lichtenegger W, Sehouli J. Impact of malnutrition on surgical outcome of patients with ovarian cancer: Results of a prospective study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16564 Background: The purpose of this study was to examine an influence of poor nutritional status on surgical outcome in patients with ovarian cancer. Methods: Data from 152 consecutive patients with histologically confirmed ovarian cancer were prospectively analyzed. Overall 79 suffered from primary and 73 from recurrent disease. All patients received a systematic nutritional assessment prior to cytoreductive surgery and postoperative all complications were analyzed in detail. The Nutritional Risk Score (NRS-2002) was used to identify patients at high nutritional risk (NRS≥3). Intraoperatively, a standardized documentation script (IMO) was applied including tumor localization, surgical interventions, and postoperative residual tumor mass. Results: 29 patients (19%) were classified as malnourished, including 19 (24%) with primary and 10 (14%) with recurrent disease. These patients showed a significantly poorer performance status preoperatively compared to patients with NRS<3 (p < 0.05), which was assessed according to the American Society of Anesthesiologists (ASA). Also an intra-operatively documented tumor spread was significantly more extended in group with NRS≥3 than among patients with NRS<3 (p < 0.05). In malnourished patients complete resection rate was significantly decreased (31% vs. 69%, p < 0.001) and they required more often a colo- or ileostoma (17% vs. 6%, p = 0.041). Malnourished patients suffered more often from post-operative complications (62% vs. 37%, p < 0.05), especially infectious like pneumonia or sepsis. All postoperative mortality events (3 cases) occurred in the malnourished group. Conclusions: Malnourished ovarian cancer patients have significantly more often post-operative complications. They suffer from more extended tumor spread and were less frequently postoperatively tumor-free. Based on our results further prospective trials of preoperative nutritional therapy to improve surgical outcome are warranted. No significant financial relationships to disclose.
Collapse
|
86
|
Schwarz J. Comparative Epidemiology of Four Deep Mycoses - a Review/Vergleichende Epidemiologie von vier tiefen (Organ-) Mykosen - eine Übersicht. Mycoses 2009. [DOI: 10.1111/j.1439-0507.1986.tb03249.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
87
|
|
88
|
|
89
|
Hesse S, Barthel H, Strecker K, Oehlwein C, Sabri O, Schwarz J. Nuklearmedizinische Diagnostik beim Parkinson-Syndrom. AKTUELLE NEUROLOGIE 2008. [DOI: 10.1055/s-2008-1067504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
90
|
Mahner S, Baasch C, Schwarz J, Wölber L, Jänicke F, Milde-Langosch K. C-Fos Expression as Predictor of Progression and Survival in Epithelial Ovarian Carcinoma. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1088673] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
91
|
Schwarz J, Darcel N, Rampin O, Andrey P, Burguet J, Fromentin G, Maurin Y, Tome D. Activation maps in the nucleus of the solitary tract (NTS) in response to internal stimuli. Appetite 2008. [DOI: 10.1016/j.appet.2008.04.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
92
|
Schwarz J, Darcel N, L’Heureux-Bouron D, Gougis S, Rampin O, Tome D, Fromentin G. Hepatic portal vein deafferentation has no effect on the satiating effect of a HP diet. Appetite 2008. [DOI: 10.1016/j.appet.2008.04.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
93
|
Schollmeier M, Becker S, Geissel M, Flippo KA, Blazević A, Gaillard SA, Gautier DC, Grüner F, Harres K, Kimmel M, Nürnberg F, Rambo P, Schramm U, Schreiber J, Schütrumpf J, Schwarz J, Tahir NA, Atherton B, Habs D, Hegelich BM, Roth M. Controlled transport and focusing of laser-accelerated protons with miniature magnetic devices. PHYSICAL REVIEW LETTERS 2008; 101:055004. [PMID: 18764401 DOI: 10.1103/physrevlett.101.055004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2008] [Indexed: 05/26/2023]
Abstract
This Letter demonstrates the transporting and focusing of laser-accelerated 14 MeV protons by permanent magnet miniature quadrupole lenses providing field gradients of up to 500 T/m. The approach is highly reproducible and predictable, leading to a focal spot of (286 x 173) microm full width at half maximum 50 cm behind the source. It decouples the relativistic laser-proton acceleration from the beam transport, paving the way to optimize both separately. The collimation and the subsequent energy selection obtained are perfectly applicable for upcoming high-energy, high-repetition rate laser systems.
Collapse
|
94
|
Moßhammer D, Muche R, Mörike K, Meznaric S, Schwarz J, Lorenz G. Prävalenz der Statinverschreibung und ihre Assoziation mit Muskelbeschwerden bei hausärztlichen Patienten – eine Querschnittsuntersuchung. DAS GESUNDHEITSWESEN 2008. [DOI: 10.1055/s-0028-1086410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
95
|
Schwarz J, Kacírková P, Marková J, Mikulenková D, Marinov I, Ballingová I, Michalová K. [Urgent states in hematology: acute promyelocytic leukemia--principles of diagnosis]. VNITRNI LEKARSTVI 2008; 54:728-744. [PMID: 18780572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A review of diagnosis of acute promyelocytic leukemia (APL) is presented. There are still many patients with progressive disease with leukocytosis at presentation. These are at greater risk of early death due to bleeding (often intracranial), or, less frequently, due to thrombotic complications. In Czechia, we have, in some instances, noted an unacceptably long time from the first symptoms to diagnosis and to administration of the highly specific differentiation therapy with tretinoin (ATRA) along with anthracycline chemotherapy. This combination is highly efficient--cures are seen in some 70% of patients. Therefore, we present a diagnostic minimum for each and every internist, and even better for every general practician, to get acquainted with. All cases of pancytopenia and consumption coagulopathy should be suspected of APL and referred to a specialized hematologist without any delay. In the following more detailed review of diagnostic measures, much attention is given to APL morphology, which is the first clue leading to diagnosis. The finding of the typical hypergranular FAB M3 morphology and of cells with bundles of Auer rods ("faggot cells"), along with the HLA-DR, CD33+ immunophenotype, is highly (but not absolutely) specific for APL. In cases of the micro-/hypo-granular variant FAB M3v Form, and whenever APL cannot be ruled out with certainty, a test to prove the presence of the PML/RARalpha fusion gene is indicated, using either RT-PCR or, eventually, immunological demonstration of the specific distribution of the PML protein in the cell nucleus. Given that morphology of APL cases, as defined according to WHO criteria (95% of which carry the PML/RARalpha fusion gene), admits extremely divergent morphological pictures ofthe variant forms, we recommend these investigations to be performed in every case of de novo acute myeloid leukemia. A review of the less frequent morphological, as well as genetic variants is given, and the principles of immunophenotypic, cytogenetic and molecular diagnostics are also reviewed.
Collapse
|
96
|
Korístek Z, Schwarz J, Zák P. [Brief case reports illustrate various initial courses in acute promyelocytic leukemia]. VNITRNI LEKARSTVI 2008; 54:771-773. [PMID: 18780576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Authors present cases which illustrate a various initial symptoms and courses of patients between the first symptoms and the diagnosis of acute promyelocytic leukemia. Symptoms indicated possible serious hematological diseases are well-known: unusual bleeding, recurrent infections or infections not responded to antibiotics, fatigue, anemia symptoms. The disease progression was sometimes very rapid, however, in certain patients the symptoms were disappreciated or even minimized and the approaches were not adequate to risks resulted from newly diagnosed acute promyelocytic leukemia.
Collapse
|
97
|
Schwarz J. [From chloroma to acute promyelocytic leukemia--a historical perspective]. VNITRNI LEKARSTVI 2008; 54:686-700. [PMID: 18780570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The progressing knowledge on chloroma and chloroleukemia is reviewed. However, it is uneasy to identify with certainty the cases of acute promyelocytic leukemia (APL) among the historical descriptions ofchloroma since 1823. In part, this is due to confusion produced by the historical cytological nomenclature--in practice, the leukemic promyelocytes were regarded, quite inaccurately, as a subtype of paramyeloblasts until early 1960's. The term promyelocytic leukemia first appeared in Naegeli's text-book in 1931. However, no clinical associations of the morphological description were then given. As a clinico-pathological entity, APLwas defined by Hillestad in Norway in 1957 and on a more detailed level, by Bernard et al in France in 1959. However, the descriptions of chloroma by Butterfield in 1909 and of leukemia with panmyelophthisis and defibrination by Risak in 1935 in the German-written literature and the case of chloroma described by Libánský in Czech in 1939 were cases of APL with high probability. Further on, experimental studies leading to the postulation of possible differentiation-inducing therapy of leukemia are reviewed--the importance of introducing of clonal culture of hematopoietic cells in the 1960's and the proof of the possibility of bypassing the maturation block in the works of Sachs's group in Rehovot, Israel, is stressed, as well as the later experiments with differentiation inducers in the cell line models in the 1970's and 1980's. The first trials with retinoids in therapy of APL are mentioned, along with the interesting background of the French-Chinese collaboration (under the auspices of professors Degos and Wang) in the introduction of retinoids into practice in the second half of the 1980's. It is discussed how the success of the clinical trials led to enormous progression in the field of molecular genetics of APL, which, in turn, led to development of a new generation of remedies, i.e. to the renaissance of arsenic in the treatment of APL in the 1990's, among others thanks to the current Chinese minister of health, Chen Zhu.
Collapse
MESH Headings
- History, 19th Century
- History, 20th Century
- History, 21st Century
- Humans
- Leukemia, Promyelocytic, Acute/diagnosis
- Leukemia, Promyelocytic, Acute/history
- Leukemia, Promyelocytic, Acute/therapy
- Sarcoma, Myeloid/diagnosis
- Sarcoma, Myeloid/history
- Sarcoma, Myeloid/therapy
Collapse
|
98
|
Penka M, Schwarz J, Pavlík T, Pytiĺk R, Doubek M, Dulícek P, Kissová J, Hlusi A, Schutzová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Dusek L. [What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]. VNITRNI LEKARSTVI 2008; 54:775-782. [PMID: 18780577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The registry of patients treated with Thromboreductine (anagrelid) in the contributing centres in the Czech Republic has been updated with data on the patients receiving this medication since 2004. The original purpose of the registry was to record responses to Thromboreductine therapy and adverse drug reactions in patients with essential thrombocytopenia. However, data on additional Ph negative myeloproliferations, as well as data on cytoreductive therapies other than exclusively that using Thromboreductine has also been recorded in the course of its compilation, including data on combined regimes. At present, the database contains data on 421 patients, and valid conclusions can be drawn if the level of data filling is enhanced. Evaluation has been currently focused on the analysis of the risk of development of clinical symptoms of thrombosis and on the standards of treatment from the viewpoint of the achieved treatment response. Analyses of data from the registry corroborate the special importance of the proof of JAK2 mutation, and of the test for factor V Leiden mutation, and of protein of S for the assessment of the risk of thromboembolic complications. The output of the analysis confirms that anagrelid is a very efficient thromboreductive agent the administration of which is associated with a low incidence of non-serious adverse effects (10.9%). However, in spite of a fast response to therapy, the therapeutic goal consisting in the reduction of the platelet count below 400 (or below 600) x 10(9)/l, i.e. the complete (or partial) treatment response, is relatively slow to achieve. This is likely to be due to lack of radical corrections in the dosage of the drug for different reasons.
Collapse
|
99
|
Schwarz J, Korístek Z, Starý J, Zák P, Kozák T, Marková J, Michalová K, Dvoráková D, Mayer J, Cetkovský P. [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors]. VNITRNI LEKARSTVI 2008; 54:757-770. [PMID: 18780575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
We have retrospectively evaluated a cohort of 144 patients (including 17 pediatric ones) with de novo acute promyelocytic leukemia registered in databases of institutions cooperating within the CELL group (The Czech Leukemia Study Group for Life). The patients were diagnosed according to WHO criteria from 1989 until 2006. The aim was to check how well fared the patients, the majority of whom was not included into clinical trials, in real life. Of 140 evaluable patients, 97 (69.3%) attained complete remission (CR). The projected overall survival (OS) 4 years after diagnosis was 58.9%, and 55.3% at 6 years. In 8 patients (6.0%), no antileukemic therapy at all was given (either they died shortly after admission to the ward or therapy was not feasible due to their clinical status). Of 125 patients with documented commencement of some kind of therapy, 96 (76.8%) achieved CR. Of 102 patients with induction treatment with a combination of anthracycline and tretinoin (ATRA), 84 individuals (82.4%) attained CR (typically, this cohort might have been subjected to clinical trials). This result was better than that of patients treated by chemotherapy only (n = 15; CR 46.7%; P = 0.003) or by ATRA monotherapy (n = 13; CR 62.5%; P = 0.17). Another parameter with a significant impact on attaining CR was the leukocyte (WBC) count at diagnosis: its median values in patients achieving and not achieving CR were 2.1 and 24.0 x 10(9)/l, respectively (P < 0.0001). The WBC counts affected OS as well (P = 0.0001). However, when only patients after attaining CR were evaluated, the initial WBC counts no longer affected OS (P = 0.18). Achieving CR was also influenced by the performance status (PS) 0-1 (P = 0.005), which was in turn closely correlated to WBC counts (P = 0.0006). Additional factors (most likely connected with leukocytosis) influenced attaining CR with borderline statistical significance: e.g. FAB M3v morphology, LDH serum level, fibrinogen level, presence of internal tandem duplication (ITD) of the FLT3 gene (which was strongly associated with leukocytosis and also with the short PML/RARalpha transcript resulting from the bcr3 break in the PML gene). It may be speculated that FLT3-ITD is just one of the possible factors that lead to leukocytosis. The platelet counts at diagnosis had no impact on entering CR. Thus, we have not validated the current PETHEMA risk stratification in distinguishing intertermediate and low risk patients. Our study points to a significant difference of the results obtained in real life and of the results that could be achieved in patients who were fit to enter clinical trials. Among the prognostic factors, the most important one was the WBC count, the PS (which is highly affected by the WBC count), and feasibility of administration of the most potent induction therapy with anthracyclines and ATRA.
Collapse
|
100
|
Schwarz J, Rambo P, Geissel M, Edens A, Smith I, Brambrink E, Kimmel M, Atherton B. Activation of the Z-petawatt laser at Sandia National Laboratories. ACTA ACUST UNITED AC 2008. [DOI: 10.1088/1742-6596/112/3/032020] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|